October 26, 2017 - La Jolla Pharmaceutical Co. (NASDAQ:LJPC) has filed a financial statement reporting Revenues of $0 USD. Previously, on July 27, 2017, La Jolla Pharmaceutical Co. reported Revenues of $0 USD.

2017-09-30 2017-Q3 0.0
2017-06-30 2017-Q2 0.0
2017-03-31 2017-Q1 0.0
2016-12-31 2016-Q4 85,000
2016-09-30 2016-Q3 44,000
2016-06-30 2016-Q2 253,000
2016-03-31 2016-Q1 234,000
2015-12-31 2015-Q4 410,000
2015-09-30 2015-Q3 647,000
2015-06-30 2015-Q2 0.0
2015-03-31 2015-Q1 0.0
2014-12-31 2014-Q4 0.0
2014-09-30 2014-Q3 0.0
2014-06-30 2014-Q2 0.0
2014-03-31 2014-Q1 0.0

Related News Stories

Your Daily Pharma Scoop: Abeona Update, Alexion Data, Solid Biosciences Setback

2018-03-16 seekingalpha
Today we will discuss Abeona Therapeutics (ABEO) after the company announced that it has nabbed a Rare Pediatric Disease designation from the FDA for ABO-202 for the treatment of CLN1 disease, which is a rare inherited disorder of the nervous system. (159-2)

4 Red-Hot Tech and Biotech Stocks to Buy With Up to 100% Upside Potential

2017-12-27 247wallst
For investors who have watched the staggering moves in bitcoin and somehow feel that they missed the bus, they were reminded last week when the cryptocurrency dropped back almost 35% just how insanely volatile the trade can be. While it may yet to prove to be the new standard for payment in the future, that sure won’t be the case anytime soon. (252-14)

PRO Weekly Digest: Special Situation, Distressed And Event-Driven Investing With Value Detective

2017-11-19 seekingalpha
How to find special situation and event-driven opportunities, merger arb and distressed investing are topics discussed and Value Detective shares a bullish thesis on PICO Holdings and Cision. (24-1)

La Jolla: Red Flags And A Vastly Overestimated Market Create A Compelling Short

2017-11-16 seekingalpha
The market potential for La Jolla's primary asset, a treatment for hypo-tension in Septic Shock patients, is severely overestimated in my opinion. (250-8)

Your Daily Pharma Scoop: Celgene's Big Fall, Tesaro VARUBI Approval, TGTX Midstage Success

2017-10-28 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (418-2)

CUSIP: 503459604